反応式
[C:1](=[O:22])(OC1C=CC([N+]([O-])=O)=CC=1)[O:2][CH2:3][CH2:4][N:5]1[CH2:10][CH2:9][N:8]([CH3:11])[CH2:7][CH2:6]1.CCN(CC)CC.[F:30][C:31]([F:45])([F:44])[C:32]1[CH:33]=[C:34]([N:38]2[CH2:43][CH2:42][NH:41][CH2:40][CH2:39]2)[CH:35]=[CH:36][CH:37]=1>CN(C=O)C>[NH3:5].[F:45][C:31]([F:30])([F:44])[C:32]1[CH:33]=[C:34]([N:38]2[CH2:43][CH2:42][N:41]([C:1]([O:2][CH2:3][CH2:4][N:5]3[CH2:6][CH2:7][N:8]([CH3:11])[CH2:9][CH2:10]3)=[O:22])[CH2:40][CH2:39]2)[CH:35]=[CH:36][CH:37]=1参加物
6
反応物 3
生成物 2
試薬・触媒・溶媒 1
実験手順
2-(4-Methylpiperazin-1-yl)ethyl 4-nitrophenyl carbonate (Intermediate 4; 761 mg, 2.5 mmol) was dissolved in DMF (20 mL). NEt3 (0.4 mL, 2.9 mmol) and 4-(3-trifluoromethyl-phenyl)piperazine (583 mg, 2.5 mmol) were added and the reaction mixture was stirred at room temperature for 24 hours, the reaction mixture was then concentrated in vacuo. The resulting residue was dissolved in EtOAc (50 mL) and washed with 1 M aq Na2CO3 solution (5×50 mL), dried (MgSO4) and concentrated in vacuo. The residue was purified by normal phase column chromatography (eluting with DCM, followed by a 100:8:1 mixture of DCM:EtOH:NH3) to give 2-(4-methylpiperazin-1-yl)ethyl 4-(3-trifluoromethyl-phenyl)piperazine-1-carboxylate (631 mg, 64%) as a colourless oil.
後処理
- concentrationthe reaction mixture was then concentrated in vacuo
- dissolutionThe resulting residue was dissolved in EtOAc (50 mL)
- washwashed with 1 M aq Na2CO3 solution (5×50 mL)
- dry with materialdried (MgSO4)
- concentrationconcentrated in vacuo
- customThe residue was purified by normal phase column chromatography (
- washeluting with DCM
- additionfollowed by a 100:8:1 mixture of DCM
出典と根拠
- ORDレコード
- ord-8139c60e46dd481ba056a1403dd7669b
- 出典データセット
- uspto-grants-2012_01
- 特許番号
- US08093248B2
関連ノート
読み込み中…